|This Slide: #26 of 100|
Slide #26. Eli Lilly and Company — Novartis Animal Health
Eli Lilly and Company (NYSE:LLY)
Novartis Animal Health
Eli Lilly and Company (NYSE: LLY) today announced an agreement to acquire Novartis Animal Health for approximately $5.4 billion in an all-cash transaction that will strengthen and diversify Lilly's own animal health business, Elanco. Upon completion of the acquisition, Elanco will be the second-largest animal health company in terms of global revenue, will solidify its number two ranking in the U.S., and improve its position in Europe and the rest of the world.
Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s human pharmaceutical products include: diabetes and other endocrinology products, immunology products, neuroscience products, oncology products, and other products. Co.'s diabetes and other endocrinology products include: Baqsimi® and Basaglar®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta® and Emgality®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux® and Verzenio®. Co.'s other products include: Cialis®.
Eli Lilly SEC Filing Email Alerts Service
Open the LLY Page at The Online Investor »
Buy (3.40 out of 4)
(ranked higher than approx. 59% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite